• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫抑制剂作用机制。

Immunosuppressive drugs modes of action.

机构信息

Nephrology and Kidney Transplantation Unit. Vall D'Hebron University Hospital, Barcelona. Spain.

University of Barcelona. Department of Clinical Sciences. Barcelona. Spain.

出版信息

Best Pract Res Clin Gastroenterol. 2021 Oct-Dec;54-55:101757. doi: 10.1016/j.bpg.2021.101757. Epub 2021 Jun 16.

DOI:10.1016/j.bpg.2021.101757
PMID:34874841
Abstract

The innate and adaptive immune systems work as a complex interplay between different cell types, involving cytokines and chemokines mediating extracellular and paracrine effects. At the intracellular level, the inflammatory cascade is mediated by multifaceted processes that have been better described in the last 10 years. Immunosuppressive agents available in clinical practice act at different points of those cascades at the intracellular or extracellular level. Those drugs can mediate their effects on one or more cell types finally limiting inflammation and immune responses to antigens. Every immunosuppressive agent is characterized by intrinsic toxicity and side effects that may be due to the same therapeutic pathways or to off-target secondary effect of each molecule. We will here review the mechanisms of action of the most widely used immunosuppressive agents in the field of solid organ transplantation and autoimmune disorders, describing the mechanisms underlying both the therapeutic and secondary effects.

摘要

先天免疫系统和适应性免疫系统通过不同细胞类型之间的复杂相互作用发挥作用,其中细胞因子和趋化因子介导细胞外和旁分泌效应。在细胞内水平,炎症级联反应由多方面的过程介导,这些过程在过去 10 年中得到了更好的描述。临床实践中可用的免疫抑制剂作用于细胞内或细胞外水平的这些级联反应的不同点。这些药物可以通过一种或多种细胞类型来发挥作用,最终限制抗原引起的炎症和免疫反应。每种免疫抑制剂都有其内在的毒性和副作用,这些副作用可能是由于相同的治疗途径,也可能是由于每个分子的非靶向次要效应。我们将在这里回顾在实体器官移植和自身免疫性疾病领域中最广泛使用的免疫抑制剂的作用机制,描述治疗作用和次要作用的潜在机制。

相似文献

1
Immunosuppressive drugs modes of action.免疫抑制剂作用机制。
Best Pract Res Clin Gastroenterol. 2021 Oct-Dec;54-55:101757. doi: 10.1016/j.bpg.2021.101757. Epub 2021 Jun 16.
2
[Immunosuppressive drugs--useful confusion of the 20th century?].[免疫抑制药物——20世纪有益的困惑?]
Ther Umsch. 1999 Dec;56(12):708-12. doi: 10.1024/0040-5930.56.12.708.
3
Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy.免疫抑制治疗药物反应的遗传学及个性化治疗前景
Mol Med Today. 2000 Dec;6(12):475-82. doi: 10.1016/s1357-4310(00)01822-0.
4
Immune monitoring to predict the development of infections after immunosuppression for solid organ transplantation and autoimmune diseases.免疫监测以预测实体器官移植和自身免疫性疾病免疫抑制后感染的发生。
Curr Drug Saf. 2008 May;3(2):91-9. doi: 10.2174/157488608784529260.
5
Immunological risk factors for infection after immunosuppressive and biologic therapies.免疫抑制和生物治疗后感染的免疫风险因素。
Expert Rev Anti Infect Ther. 2011 Apr;9(4):405-13. doi: 10.1586/eri.10.178.
6
The Effect of Immunosuppressive Drugs on MDSCs in Transplantation.免疫抑制剂对移植中 MDSCs 的影响。
J Immunol Res. 2018 Jul 3;2018:5414808. doi: 10.1155/2018/5414808. eCollection 2018.
7
Current landscape for T-cell targeting in autoimmunity and transplantation.自身免疫和移植中 T 细胞靶向的现状。
Immunotherapy. 2011 Jul;3(7):853-70. doi: 10.2217/imt.11.61.
8
Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.实体器官移植中的免疫抑制剂:作用机制与治疗效果
Crit Rev Oncol Hematol. 2005 Oct;56(1):23-46. doi: 10.1016/j.critrevonc.2005.03.012.
9
[Molecular mechanisms of action of some immunosuppressive drugs].[一些免疫抑制药物的分子作用机制]
Medicina (B Aires). 2008;68(6):455-64.
10
Editorial: Immune monitoring in solid organ transplantation.社论:实体器官移植中的免疫监测
Clin Biochem. 2016 Mar;49(4-5):317-9. doi: 10.1016/j.clinbiochem.2016.01.005. Epub 2016 Jan 12.

引用本文的文献

1
Translating Antiviral Therapies to Veterinary Use: A Review of Immunomodulatory Agents for Potential Application in Aleutian Mink Diseases.将抗病毒疗法转化为兽用:用于水貂阿留申病潜在应用的免疫调节剂综述
Animals (Basel). 2025 Aug 11;15(16):2360. doi: 10.3390/ani15162360.
2
Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants.霉酚酸治疗促使新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体出现。
Proc Natl Acad Sci U S A. 2025 Jul 15;122(28):e2500276122. doi: 10.1073/pnas.2500276122. Epub 2025 Jul 9.
3
Pharmacodynamic effect of mTOR inhibition-based immunosuppressive therapy on dendritic cell and natural killer cell subsets after renal transplantation.
基于mTOR抑制的免疫抑制疗法对肾移植后树突状细胞和自然杀伤细胞亚群的药效学作用。
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf026.
4
Side Effects of Immunosuppressant Drugs After Liver Transplant.肝移植后免疫抑制药物的副作用
Pharmaceuticals (Basel). 2025 Feb 27;18(3):342. doi: 10.3390/ph18030342.
5
Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study.使用长期肿瘤坏死因子-α抑制剂的银屑病和类风湿关节炎患者发生血液系统恶性肿瘤的风险:一项全国性回顾性研究。
Sci Rep. 2025 Mar 7;15(1):7949. doi: 10.1038/s41598-025-90996-z.
6
Current status of pancreatic islet xenotransplantation.胰岛异种移植的现状
Clin Transplant Res. 2025 Mar 31;39(1):1-11. doi: 10.4285/ctr.24.0046. Epub 2025 Feb 10.
7
Duvelisib is a novel NFAT inhibitor that mitigates adalimumab-induced immunogenicity.度维利塞是一种新型的NFAT抑制剂,可减轻阿达木单抗诱导的免疫原性。
Front Pharmacol. 2025 Jan 9;15:1397995. doi: 10.3389/fphar.2024.1397995. eCollection 2024.
8
Correlation and diagnostic significance of CD4 T cell subsets and NLRP3 inflammasome in ulcerative colitis: the role of the NLRP3/T-bet/GATA3 axis.CD4 T细胞亚群与NLRP3炎性小体在溃疡性结肠炎中的相关性及诊断意义:NLRP3/T-bet/GATA3轴的作用
BMC Gastroenterol. 2025 Jan 21;25(1):23. doi: 10.1186/s12876-025-03603-w.
9
Autoimmune diseases refractory to corticosteroids and immunosuppressants.自身免疫性疾病,对皮质类固醇和免疫抑制剂有抗药性。
Front Immunol. 2024 Sep 16;15:1447337. doi: 10.3389/fimmu.2024.1447337. eCollection 2024.
10
Evaluation of THP-1 and Jurkat Cell Lines Coculture for the In Vitro Assessment of the Effects of Immunosuppressive Substances.用于体外评估免疫抑制物质作用的THP-1和Jurkat细胞系共培养的评估
Toxics. 2024 Aug 19;12(8):607. doi: 10.3390/toxics12080607.